Skip To Main Content
Bart L Haagmans on Muck Rack

Bart L Haagmans

As seen in: Color Research & Application, Nature, Journal of Automated Methods and Management in Chemistry, BioRxiv, The Lancet, Annual Reviews Journal, Microbiology Research
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Bart L

Contact Bart L, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Mapping SARS-CoV-2 immunity after an XBB.1.5 booster by antigenic cartography of merged human and hamster sera

|
By Marta Bermejo-Jambrina, Antonia Netzl, Ludwig Knabl, Melanie Schmitt, Annika Rössler, Gagandeep Singh, Seok-Chan Park, Michael Schotsaert, Anna Z Mykytyn, Bart L Haagmans, Wegene Borena, Derek Smith, Janine Kimpel
| Nature Verified
Abstract The ongoing evolution of SARS-CoV-2, particularly the emergence and rapid spread of new immune-evasive variants, continues to challenge the durability of vaccine-induced protection. Understanding how repeated variant exposures shape neutralizing antibody breadth is therefore essential for optimizing booster design.
Open in Who Shared Issue with article?

Human MERS-CoV cases are falling but pose an ongoing pandemic threat

|
By Lorenzo Subissi, James R. Otieno, Laith Jamal Abu-Raddad, Anurag Agrawal, Amal Z. Barakat, Leon Caly, Meera A Chand, Christian Drosten, Nuno R Faria, Adeola Fowotade, Anne von Gottberg, Bart L Haagmans, Baoying Huang, Jason Kindrachuk, Marion Koopmans, Bette Korber, Yee-Sin Leo, Placide Mbala-Kingebeni, Nada M Melhem, Vincent J. Munster, Isaac Ngere, M. Kariuki Njenga, Tulio de Oliveira, Gustavo Palacios, Malik Peiris, Andrew Rambaut, Paola Cristina Resende, Senjuti Saha, Tadaki Suzuki, Pragya D. Yadav, Sophie von Dobschuetz, Esam I Azhar, Maria Van Kerkhove, Ahmed Mohammed Albarraq, Ismail Mahat Bashir
| Nature Verified
Human cases of Middle East respiratory syndrome coronavirus (MERS-CoV) have declined in recent years, but continued surveillance and research is needed to understand this trend and mitigate future zoonotic threats.
Open in Who Shared Issue with article?

Two-year persistence of MERS-CoV-specific antibody and T cell responses after MVA-MERS-S vaccination in healthy adults - Nature Communications

|
By Leonie Mayer, Matthijs P. Raadsen, Anna Z Mykytyn, Leonie M. Weskamm, Marc Lütgehetmann, Christian Drosten, Bart L Haagmans, Svenja Hardtke, Hanna-Marie Weichel
| Nature Verified
Abstract MVA-MERS-S, a vaccine candidate against Middle East respiratory syndrome (MERS), was recently evaluated in a randomized, placebo-controlled, double-blind phase 1b clinical trial to assess its safety, immunogenicity, and optimal dosing in healthy adults in Hamburg and Rotterdam. A three-dose regimen was safe and elicited robust spike-specific antibody responses.
Open in Who Shared Issue with article?
See all 33 articles